ReviewThe American journal of medicine2017
Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease.
Review in The American journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 5 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Pharmacological therapies for alcohol use disorder reduce hepatic decompensation & mortality in alcohol-related liver disease: A GRADE evaluation through a meta-analysis.The Indian journal of medical research · 2025Pooled it
- Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.Alcoholism, clinical and experimental research · 2019Pooled it
- Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol.Internal and emergency medicine · 2019Guideline
- ACG Clinical Guideline: Alcoholic Liver Disease.The American journal of gastroenterology · 2018Guideline
- Simultaneous Management of Alcohol Use Disorder and Liver Disease: A Systematic Review and Meta-analysis.Journal of addiction medicinePooled it
- Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.JAMA internal medicine · 2020Trial
- Challenges, Potential Solutions in Recruiting and Retaining Participants for Alcohol Use Disorder Research: A Literature Review.Healthcare (Basel, Switzerland) · 2026Review
- Implementation of Mobile-Based Programs for Alcohol Cessation in the Treatment of Alcohol-associated Liver Disease: Protocol for a Type 1 Hybrid Implementation-Effectiveness Trial.JMIR research protocols · 2026Article
- Identification of an IRF-ZBP1-caspase-8-NINJ1 axis in driving PANoptosis and pathology during alcohol-associated liver disease.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Effect of varenicline on major adverse liver outcomes in alcohol-associated liver disease: An exploratory analysis.Alcohol, clinical & experimental research · 2025Article
- Kv1.3 knockdown attenuates alcohol-related liver injury in mice through induction of tryptamine.Acta pharmacologica Sinica · 2025Article
- Role of cystathionine-β-synthase and hydrogen sulfide in down syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Burden of Alcohol-Related Liver Disease and Alcohol Use Disorder in Asia.United European gastroenterology journal · 2025Article
- Trends and cross-country inequalities of alcohol use disorders: findings from the global burden of disease study 2021.Globalization and health · 2025Article
- Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021.Clinical and molecular hepatology · 2025Article
- Fatal Disulfiram-Ethanol Reaction in a Patient With Preexisting Cardiac Comorbidities: A Case Report.Cureus · 2025Article
- The critical role of the ZBP1-NINJ1 axis and IRF1/IRF9 in ethanol-induced cell death, PANoptosis, and alcohol-associated liver disease.bioRxiv : the preprint server for biology · 2025Article
- Gut Microbiome-Liver-Brain axis in Alcohol Use Disorder. The role of gut dysbiosis and stress in alcohol-related cognitive impairment progression: possible therapeutic approaches.Neurobiology of stress · 2025Article
- Just a SNP away: The future ofCell insight · 2025Review
- Alcohol-Associated Hepatitis: Short- and Long-Term Management.Digestive diseases and sciences · 2025Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Alcohol is a leading cause of liver disease worldwide. Although alcohol abstinence is the crucial therapeutic goal for patients with alcoholic liver disease, these patients have less access to psychosocial, behavioral, and/or pharmacologic treatments for alcohol use disorder. Psychosocial and behavioral therapies include 12-step facilitation, brief interventions, cognitive behavioral therapy, and motivational enhancement therapy. In addition to medications approved by the US Food and Drug Administration for alcohol use disorder (disulfiram, naltrexone, and acamprosate), recent efforts to identify potential new treatments have yielded promising candidate pharmacotherapies. Finally, more efforts are needed to integrate treatments across disciplines toward patient-centered approaches in the management of patients with alcohol use disorder and alcoholic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.